DUBLIN, Feb. 15, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Cancer Nanomedicine Market Outlook 2022" report to their offering.

The future of cancer nanotechnology lies on a multifunctional nanoplatform that combines both therapeutic components and multimodality imaging. The ultimate goal is that multifunctional nanomedicine works as efficient, targeted in vivo drug delivery without systemic toxicity, and the dose delivered as well as the therapeutic efficacy can be accurately measured noninvasively with time. In the future, nanotechnology could possibly be strategically implemented in new developing drug delivery systems which could lead to significant expansion in the drug markets.

These new drug delivery methods are likely to provide the appropriate platform for the pharmaceutical companies to reformulate their existing drugs in the market. This would in turn lead to extending the life of their products and ensuring an improved performance of drugs by increasing effectiveness, safety and patient adherence, and ultimately reducing healthcare costs.

Global Cancer Nanomedicine Market Outlook 2022 Report Highlights:

- Overview & Mechanism of Action of Nanomedicine

- Nanomedicine Engineering: Design & Strategy

- Cancer Nanomedicine as Diagnostic & Therapeutics Tool

- Global Cancer Nanomedicine Market Overview & Dynamics

- Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase

- Global Cancer Nanomedicine Clinical Pipeline: 124 Drug

- Marketed Cancer Nanomedicine: 8 Drugs

Key Topics Covered:

1. Cancer Nanomedicine: An Optimistic Avenue

1.1 Introduction

1.2 Emergence of Nanomedicines

2. Prerequisite of Nanomedicines

2.1 Conventional Cancer Treating Approaches

2.2 Nanomedicines: Overcoming the Hurdles

3. Diversification of Nanomedicines

3.1 Classification on Basis of Constituents

3.1.1 Inorganic Nanoparticles

3.1.2 Organic Nanoparticles

3.2 Classification on Basis of Applicability

3.2.1 Nanomedicine as Diagnostic Agents

3.2.2 Nanomedicine as Therapeutic Agents

3.2.3 Nanomedicine as Drug Delivery Agents

3.3 Classification on Basis of Dimensions

4. Mechanism of Action of Nanomedicine

4.1 Targeting Tumor Cells

4.1.1 Passive Targeting

4.1.2 Active Targeting

4.2 Nanocarrier - Drug Complex

4.2.1 Liposomes

4.2.2 Dendrimers

4.2.3 Micelles

4.2.4 Inorganic Nanocarriers

4.3 Drug Release Systems

5. Nanomedicine Engineering: Design & Strategy

5.1 Organic Nanoparticles as Nanomedicines

5.1.1 Polymeric Nanoparticle

5.1.2 Lipid Organic Nanoparticles

5.2 Inorganic Nanoparticles as Nanomedicines

5.2.1 Synthesis of Gold Nanoparticle

6. Cancer Nanomedicine as Diagnostic Tool

6.1 Detection of Cancer Biomarkers

6.1.1 Detection of Circulating Tumor Cell

6.2 Diagnostic Device & Nanoprobes

6.2.1 Biosensors

6.2.2 Microarrays

6.3 Quantum Dots for Early Cancer Detection

6.3.1 Detection of primary Cancers

6.3.2 Quantum Dots for Tumor Imaging

7. Cancer Therapeutics with Nanomedicines

7.1 Nanomedicine as Therapeutic Agents

7.1.1 Photodynamic Therapy

7.1.2 Photo Thermal Therapy

7.2 Nanomedicines as Prophylactic & Therapeutic Approach

7.2.1 Cancer Cell Destruction

7.3 Nanomedicine in Breast Cancer

7.4 Nanomedicine in Pancreatic Cancer

7.5 Nanomedicine in Brain Cancer

7.6 Nanomedicine in Lung Cancer

8. Cancer Imaging with Nanomedicine

8.1 Positron Emission Tomography

8.1.1 Applications in various Cancers

8.2 Single Photon Emitted Tomography

8.2.1 Computed Tomography

8.3 Magnetic Resonance Imaging (MRI)

8.3.1 Optical Imaging

9. Drug Delivery with Nanomedicines

9.1 Nanocarrier & Chemotherapy

9.1.1 Peptide Nanomedicine- An Example of Nanocarrier Chemotherapy

9.2 Nanomedicine Endocytosis & Intracellular Mechanisms

9.3 Factors Affecting Drug Delivery

10. Global Cancer Nanomedicine Market Overview

10.1 Current Market Scenario

10.2 Global Cancer Nanomedicine Clinical Pipeline Overview

11. Global Nanomedicine Market Dynamics

11.1 Encouraging Market Aspects

11.2 Commercialization Challenges

12. Global Cancer Nanomedicine Future Prospect

13. Global Cancer Nanomedicine Clinical Pipeline by Company, Indication & Phase

13.1 Research

13.2 Preclinical

13.3 Phase-I

13.4 Phase-I/II

13.5 Phase-II

13.6 Phase-III

14. Marketed Cancer Nanomedicine Clinical Insight by Company, Indication & Phase

14.1 Doxorubicin Liposomal (Caelyx & Doxil)

14.2 Albumin-Bound Paclitaxel (Abraxane & Coraxane)

14.3 Nilotinib (Tasigna)

14.4 Paclitaxel Polymeric Micelle Formulation (Cynviloq & Genexol-PM)

14.5 Paclitaxel Liposomal

14.6 Vincristine Liposomal (Marqibo)

14.7 Rexin-G

14.8 Paclitaxel Nanoparticle (Nanoxel)

15. Competitive Landscape

15.1 Abraxis BioScience

15.2 Access Pharmaceuticals

15.3 Alnylam Pharmaceuticals

15.4 Amgen

15.5 Arrowhead Research

15.6 BIND Therapeutics

15.7 Cadila Healthcare

15.8 Celegen Corporation

15.9 Celsion Corporation

15.10 Genzyme Corporation

15.11 Merck

15.12 NanoCarrier

15.13 Nippon Kayaku

15.14 Nanobiotix

15.15 Novavax

15.16 Pfizer

15.17 Roche

15.18 Samyang

15.19 Sanofi

15.20 Takeda Pharmaceutical

For more information about this report visit http://www.researchandmarkets.com/research/8q3fcs/global_cancer

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets